Metastatic melanoma: therapeutic agents in preclinical and early clinical development.

Metastatic melanoma: therapeutic agents in preclinical and early clinical development. Expert Opin Investig Drugs. 2020 May 13;: Authors: Boos L, Leslie I, Larkin J Abstract Introduction: Advanced melanoma historically had a very poor outcome but targeted therapies and immune checkpoint inhibitors (IC) have changed the course of the disease and made durable responses possible. However, most patients will develop progressive disease, so further strategies to overcome treatment resistance are needed.Areas covered: Current treatment strategies and landmark trials are discussed.Novel targeted agents, immune checkpoint inhibitors and further immune-modulatory drugs, cancer vaccines and tumour infiltrating lymphocytes and their potential role in the treatment of melanoma are described. Current trials investigating these emerging agents and treatment strategies were searched for on ClinicalTrials.gov and are presented on the background of the current literature explaining the rationale for employing these new agents and strategies. Combinations of tumour-directed agents with those causing immune augmentation as well as new adjuvant and neoadjuvant strategies are discussed.Expert Opinion: Questions regarding treatment combination, personalisation and sequence of treatment will become increasingly important and will be guided by new biomarkers. New treatment settings will broaden patient selection and will highlight the need for further discu...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research